Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quoin Pharmaceuticals Ltd QNRX

Healthcare Biotechnology
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology... see more

Recent & Breaking News (NDAQ:QNRX)

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

GlobeNewswire November 3, 2023

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

GlobeNewswire October 24, 2023

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

GlobeNewswire October 24, 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

GlobeNewswire August 2, 2023

Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET

GlobeNewswire July 27, 2023

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

GlobeNewswire May 24, 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

GlobeNewswire May 8, 2023

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

GlobeNewswire May 2, 2023

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

GlobeNewswire March 21, 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 8, 2023

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

GlobeNewswire March 2, 2023

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

GlobeNewswire February 22, 2023

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

GlobeNewswire December 13, 2022

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

GlobeNewswire November 3, 2022

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

GlobeNewswire November 1, 2022

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

GlobeNewswire October 18, 2022

Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

GlobeNewswire September 13, 2022

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

GlobeNewswire August 18, 2022

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

GlobeNewswire August 11, 2022